股本结构
单位：万股
| 公告日期 | 2025-11-10 | 2025-11-10 | 2025-08-06 | 2025-07-31 | 2025-08-04 | 2025-05-08 |
|---|---|---|---|---|---|---|
| 证券总股本 | 4237.10 | 4191.91 | 4172.07 | 3298.77 | 3255.29 | 2975.27 |
| 普通股本 | 4237.10 | 4191.91 | 4172.07 | 3298.77 | 3255.29 | 2975.27 |
| 优先股 | 未披露 | 0.17 | 未披露 | 未披露 | 0.17 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-10 | 2025-09-30 | 2025-08-01 | 2025-07-31 | 2025-06-30 | 2025-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-10 | 4237.10 | 未披露 | 定期报告 | 2025-11-10 |
| 2025-11-10 | 4191.91 | 0.17 |
更多>>
From July 30, 2025 to September 30, 2025
Exercise of pre-funded warrants
Exercise of Warrants Series I to 10,561,685 pre-funded warrants and 943,641 common stock, net of $891 issuance costs
Issuance of common stock, included at the market offering and 9,764,804 pre-funded warrants net of $3,126 issuance costs
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 34,712 shares
|
2025-09-30 |
| 2025-08-06 | 4172.07 | 未披露 | 定期报告 | 2025-08-01 |
| 2025-07-31 | 3298.77 | 未披露 |
更多>>
The Series I warrants were converted into 2,352,393 common shares
|
2025-07-31 |
| 2025-08-04 | 3255.29 | 0.17 |
更多>>
From April 1, 2025 to June 30, 2025
Exercise of pre-funded warrants
Exercise of Warrants Series I to common stock, net of $109 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 258,912 shares
|
2025-06-30 |
| 2025-04-15 | 3063.53 | 未披露 | 定期报告 | 2025-04-15 |
| 2025-05-08 | 2975.27 | 0.17 |
更多>>
From January 1, 2025 to March 31, 2025
Exercise of pre-funded warrants
Issuance of common stock, included at the market offering net of $22 issuance costs
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 29,295 shares
|
2025-03-31 |
| 2025-03-12 | 2968.99 | 未披露 | 定期报告 | 2025-03-12 |
| 2025-03-12 | 2661.10 | 0.17 |
更多>>
From January 1, 2024 to December 31, 2024
Balance, value
Exercise of pre-funded warrants
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs
Issuance of common stock, included at the market offering net of $81 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 128,660 shares
|
2024-12-31 |
| 2024-11-12 | 2608.38 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-11-12 | 2571.96 | 0.17 |
更多>>
From July 1, 2024 to September 30, 2024
Exercise of pre-funded warrants
Issuance of common shares, Included at the market offering net of $1 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award
|
2024-09-30 |
| 2024-08-05 | 2570.67 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-07-01 | 2525.34 | 未披露 |
更多>>
On July 1, 2024, InspireMD, Inc. Announced the completion of the full exercise of 12.9 million of the Company's Series H warrants. The Series H warrants were converted into 292,996 of common shares.
|
2024-07-01 |
| 2024-08-05 | 2519.65 | 0.17 |
更多>>
From April 1, 2024 to June 30, 2024
Exercise of pre-funded warrants
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 37,292 shares
|
2024-06-30 |
| 2024-05-31 | 2496.05 | 未披露 | 定期报告 | 2024-05-30 |
| 2024-05-13 | 2492.98 | 未披露 | 定期报告 | 2024-05-13 |
| 2024-04-18 | 2342.42 | 未披露 | 定期报告 | 2024-04-18 |
| 2024-05-13 | 2341.24 | 0.17 |
更多>>
From January 1, 2024 to March 31, 2024
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 75,090 shares
|
2024-03-31 |
| 2024-03-05 | 2345.66 | 未披露 | 定期报告 | 2024-03-05 |
| 2024-03-05 | 2184.12 | 0.17 |
更多>>
From January 1, 2023 to December 31,2023
Exercise of pre-funded warrants
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 29,695 shares
|
2023-12-31 |
| 2023-11-06 | 2154.96 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-06 | 2140.02 | 0.17 |
更多>>
From July 1, 2023 to September 30, 2023
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 9,749 shares
|
2023-09-30 |
| 2023-07-28 | 2119.51 | 未披露 | 定期报告 | 2023-07-18 |
| 2023-08-07 | 2119.22 | 0.17 | 定期报告 | 2023-06-30 |
| 2023-05-23 | 2119.22 | 未披露 | 定期报告 | 2023-05-19 |
| 2023-05-15 | 835.64 | 未披露 | 定期报告 | 2023-05-14 |
| 2023-05-15 | 832.66 | 0.17 |
更多>>
From January 1, 2023 to March 31, 2023
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 4,270 shares
|
2023-03-31 |
| 2023-03-30 | 832.66 | 未披露 | 定期报告 | 2023-03-28 |
| 2023-03-30 | 833.09 | 0.17 |
更多>>
From December 31, 2021 to December 31, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 10,832 shares
|
2022-12-31 |
| 2022-11-07 | 833.56 | 0.17 |
更多>>
From July 1, 2022 to September 30, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 1,581 shares
|
2022-09-30 |
| 2022-08-08 | 832.32 | 0.17 |
更多>>
From April 1, 2022 to June 30, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award
|
2022-06-30 |
| 2022-05-09 | 832.32 | 未披露 | 定期报告 | 2022-05-04 |
| 2022-05-09 | 831.79 | 0.17 |
更多>>
From January 1, 2022 to March 31, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 4,563 share
|
2022-03-31 |
| 2022-03-07 | 832.24 | 未披露 | 定期报告 | 2022-03-04 |
| 2022-03-07 | 829.63 | 0.17 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common shares, including at the market offering net of $2,024 issuance costs
Exercise of Warrants F
Exercise of Warrants G
Conversion of Series B Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 20,822 shares
Round up of shares due to reverse stock split effectuated on April 26, 2021
|
2021-12-31 |
| 2021-11-08 | 807.70 | 未披露 | 定期报告 | 2021-11-04 |
| 2021-11-08 | 790.03 | 0.17 |
更多>>
From July 1, 2021 to September 30, 2021
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 13,077 shares
Round up of shares due to reverse stock split effectuated on April 26, 2021
|
2021-09-30 |
| 2021-08-12 | 791.49 | 未披露 | 定期报告 | 2021-08-12 |
| 2021-08-09 | 791.38 | 未披露 | 定期报告 | 2021-08-06 |
| 2021-08-09 | 791.43 | 0.17 |
更多>>
From April 1, 2021 to June 30, 2021
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 2,683 shares
Round up of shares due to reverse stock split effectuated on April 26, 2021
|
2021-06-30 |
| 2021-05-10 | 790.65 | 未披露 | 定期报告 | 2021-05-10 |
| 2021-05-10 | 785.28 | 0.17 |
更多>>
From January 1, 2021 to April 27, 2021
Issuance of common shares, including at the market offering net of $2,018 issuance costs
Exercise of Warrants F
Exercise of Warrants G
Conversion of Series B Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 3,276 shares
InspireMD, Inc. today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. The number of authorized shares of the Company’s common stock will remain at 150,000,000, while the number of outstanding shares will be reduced from approximately 118.0 million to 7.9 million. No fractional shares will be issued following the reverse stock split.
|
2021-04-27 |
| 2021-04-05 | 11779.19 | 未披露 | 定期报告 | 2021-03-25 |
| 2021-03-08 | 11783.22 | 未披露 | 定期报告 | 2021-03-08 |
| 2021-02-11 | 11119.31 | 未披露 |
更多>>
1.Units offered by the company: 29,032,258 units, each consisting of one share of common stock.
2.Based on 71,835,287 shares of common stock outstanding as of February 3, 2021.
|
2021-02-08 |
| 2021-02-09 | 7619.01 | 未披露 | 定期报告 | 2021-02-04 |
| 2021-02-05 | 7183.53 | 1.96 | 定期报告 | 2021-02-03 |
| 2021-01-29 | 7145.56 | 1.96 | 定期报告 | 2021-01-26 |
| 2021-01-19 | 6165.57 | 1.96 | 定期报告 | 2021-01-14 |
| 2021-03-08 | 4926.48 | 1.96 |
更多>>
From December 31, 2019 to December 31, 2020
Exercise of pre-funded warrants
Settlement of restricted stock units in shares of common stock
Issuance of common shares, including at the market offering net of $1,110 issuance costs
Exercise of Warrants F
Exercise of Unit Purchase Option
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 55,755 shares
|
2020-12-31 |
| 2020-11-09 | 3695.48 | 未披露 | 定期报告 | 2020-11-05 |
| 2020-11-09 | 3605.91 | 1.96 |
更多>>
From July 1, 2020 to September 30, 2020
Issuance of common shares at the market offering, net of $110 issuance costs
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 1,484 shares
|
2020-09-30 |
| 2020-07-28 | 3335.77 | 未披露 | 定期报告 | 2020-07-28 |
| 2020-08-05 | 3335.90 | 未披露 |
更多>>
From April 1, 2020 to June 30, 2020
Exercise of pre-funded warrants
Issuance of common shares, net of $835 issuance costs
Exercise of Warrants F
Exercise of Unit Purchase Option to common shares
Conversion of Series C Convertible Preferred Stock to common shares
|
2020-06-30 |
| 2020-06-05 | 1197.47 | 未披露 |
更多>>
1.Units offered by us 7,635,800 units, each consisting of one share of our common stock and/or one Series F Warrant to purchase one share of our common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 4,338,910 shares of our common stock outstanding as of June 2, 2020
|
2020-06-05 |
| 2020-05-11 | 433.89 | 4.39 |
更多>>
From January 1, 2020 to March 31, 2020
Exercise of pre-funded warrants
Settlement of restricted stock units in shares of common stock
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 40,000 shares
|
2020-03-31 |
| 2020-03-10 | 433.89 | 未披露 | 定期报告 | 2020-03-09 |
| 2020-03-10 | 391.61 | 5.17 |
更多>>
from December 31, 2018 to December 31, 2019
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of $1,177 issuance costs
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of 838 shares
|
2019-12-31 |
| 2019-11-12 | 363.29 | 未披露 | 定期报告 | 2019-11-12 |
| 2019-11-12 | 345.69 | 5.42 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of $710 issuance costs
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 142 shares
|
2019-09-30 |
| 2019-09-24 | 193.83 | 未披露 | 定期报告 | 2019-09-24 |
| 2019-09-23 | 139.93 | 5.43 | 定期报告 | 2019-09-19 |
| 2019-08-23 | 139.84 | 未披露 | 定期报告 | 2019-08-22 |
| 2019-08-05 | 139.83 | 未披露 | 定期报告 | 2019-08-05 |
| 2019-08-05 | 139.71 | 5.61 |
更多>>
from March 31, 2019 to June 30,2019
Issuance of common shares, net of $467 issuance costs
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 483 shares
|
2019-06-30 |
| 2019-05-13 | 139.77 | 未披露 | 定期报告 | 2019-05-10 |
| 2019-05-13 | 87.19 | 7.67 |
更多>>
From December 31, 2018 to April 1, 2019
Exercise of pre-funded warrants
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 212 shares
InspireMD, Inc. announced that its Board of Directors has approved a one-for-fifty reverse stock split of its common stock that is scheduled to become effective after trading closes on March 29, 2019. The number of authorized shares of the Company’s common stock will remain at 150,000,000, while the number of outstanding shares will be reduced from approximately 44 million to 0.9 million. No fractional shares will be issued following the reverse stock split.
|
2019-04-01 |
| 2019-02-19 | 4188.89 | 未披露 | 定期报告 | 2019-02-15 |
| 2019-02-19 | 3840.90 | 7.87 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common shares, warrants, Pre-funded warrants and exercise of pre-funded warrants, net of $2,206 issuance costs
Conversion of Series B Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares
Exercise of Unit Purchase Option
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 201 shares
Classification of Series C Convertible Preferred Stock
Redemption of Series D Preferred Stock
|
2018-12-31 |
| 2018-11-06 | 3760.40 | 未披露 | 定期报告 | 2018-11-05 |
| 2018-11-06 | 3669.40 | 7.87 |
更多>>
From December 31, 2017 to September 30, 2018
Issuance of common shares, warrants, Pre-funded warrants and exercise of pre-funded warrants, net of $2,171 issuance costs
Conversion of Series B Preferred Stock to common shares
Conversion of Series C Preferred Stock to common shares
Exercise of Unit Purchase Option
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 121 shares
Redemption of Series C Preferred Stock
Redemption of Series D Preferred Stock
|
2018-09-30 |
| 2018-09-11 | 2378.48 | 未披露 | 定期报告 | 2018-09-06 |
| 2018-08-06 | 2378.48 | 未披露 | 定期报告 | 2018-08-06 |
| 2018-08-06 | 645.34 | 39.64 |
更多>>
From December 31, 2017 to JUNE 22, 2018
Issuance of common shares, net of $1,053 issuance costs
Redemption of Series D Preferred Stock
Conversion of Series B Preferred Stock to common shares
Conversion of Series C Preferred Stock to common shares
Exercise of Unit Purchase Option
Redemption of Series C Preferred Stock
|
2018-06-22 |
| 2018-05-07 | 644.98 | 未披露 | 定期报告 | 2018-05-04 |
| 2018-05-07 | 350.13 | 46.93 |
更多>>
From December 31, 2017 to March 31, 2018
Issuance of common shares, net of $496 issuance costs
Redemption of Series D Preferred Stock
Conversion of Series B Preferred Stock to common shares
Conversion of Series C Preferred Stock to common shares
Exercise of Unit Purchase Option
|
2018-03-31 |
| 2018-03-08 | 297.92 | 未披露 | 定期报告 | 2018-03-07 |
| 2018-02-13 | 167.56 | 未披露 | 定期报告 | 2018-02-12 |
| 2018-02-13 | 148.38 | 76.95 |
更多>>
from December 31, 2016 to February 8, 2018
Issuance of preferred shares and warrants, net of $776 issuance costs
Issuance of preferred shares, net of $90 issuance costs
Conversion of preferred B shares to common shares
Conversion of preferred C shares to common shares
Share-based compensation related to restricted stock award, net of forfeitures of 202 shares
Taxes withheld in respect of share issuance
InspireMD, Inc. today announced a 1-for-35 reverse split of its common stock, effective as of February 7, 2018. Beginning on February 8, 2018.The number of authorized shares of the Company's common stock will remain at 150,000,000, while the number of outstanding shares will be reduced from approximately 58.6 million to 1.7 million.
|
2018-02-08 |
| 2017-12-26 | 5191.57 | 未披露 | 定期报告 | 2017-12-15 |
| 2017-11-07 | 746.59 | 92.42 | 定期报告 | 2017-09-30 |
| 2017-08-29 | 746.59 | 未披露 | 定期报告 | 2017-08-28 |
| 2017-08-08 | 745.10 | 未披露 | 定期报告 | 2017-08-08 |
| 2017-08-08 | 746.76 | 92.71 | 定期报告 | 2017-06-30 |
| 2017-05-09 | 742.18 | 未披露 | 定期报告 | 2017-05-09 |
| 2017-05-10 | 742.18 | 未披露 | 定期报告 | 2017-05-08 |
| 2017-05-09 | 683.01 | 100.06 | 定期报告 | 2017-03-31 |
| 2017-02-17 | 147.26 | 31.15 | 定期报告 | 2017-02-15 |
| 2017-02-17 | 147.53 | 31.15 |
更多>>
from December 31, 2015 to December 31, 2016
Issuance of common stock, preferred shares and warrants, net of $1,966 issuance costs
Conversion of preferred shares to common shares
Share-based compensation related to restricted stock award, net of forfeitures of 1,266 shares
Exercise of options by employee and non-employee
Issuance of shares for options cancelled
Taxes withheld in respect of share issuance
The company today announced a 1-for-25 reverse split of its common stock, effective as of October 7, 2016. Beginning on October 10, 2016, the Company's common stock will trade on the NYSE MKT on a split adjusted basis.
|
2016-12-31 |
| 2016-11-14 | 143.25 | 未披露 | 定期报告 | 2016-11-11 |
| 2016-11-14 | 134.02 | 31.20 |
更多>>
The company today announced a 1-for-25 reverse split of its common stock, effective as of October 7, 2016. Beginning on October 10, 2016, the Company's common stock will trade on the NYSE MKT on a split adjusted basis.
|
2016-10-10 |
| 2016-08-19 | 3189.76 | 未披露 | 定期报告 | 2016-08-15 |
| 2016-08-18 | 3057.20 | 未披露 | 定期报告 | 2016-08-11 |
| 2016-08-09 | 2987.20 | 未披露 | 定期报告 | 2016-08-09 |
| 2016-07-15 | 1067.56 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-06-14 | 1070.13 | 未披露 | 定期报告 | 2016-06-14 |
| 2016-05-10 | 1072.11 | 未披露 | 定期报告 | 2016-05-10 |
| 2016-05-04 | 1072.11 | 未披露 | 定期报告 | 2016-04-27 |
| 2016-04-14 | 1072.30 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-28 | 1072.68 | 未披露 | 定期报告 | 2016-03-28 |
| 2016-03-28 | 767.61 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of shares and warrants, net of $1,315 issuance costs
Vesting of restricted stock
Taxes withheld in respect of share issuance
On October 1, 2015, the Company effectuated a one-for-ten reverse stock split of its common stock.
|
2015-12-31 |
| 2015-11-09 | 778.53 | 未披露 | 定期报告 | 2015-11-09 |
| 2015-11-09 | 763.28 | 未披露 |
更多>>
On September 30, 2015, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse stock split of its common stock
|
2015-10-01 |
| 2015-08-05 | 7785.63 | 未披露 | 定期报告 | 2015-08-05 |
| 2015-07-29 | 7787.05 | 未披露 | 定期报告 | 2015-07-27 |
| 2015-08-05 | 7604.84 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-11 | 7799.53 | 未披露 | 定期报告 | 2015-05-11 |
| 2015-05-11 | 7594.06 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-12 | 7815.20 | 未披露 | 定期报告 | 2015-03-11 |
| 2015-03-12 | 4136.89 | 未披露 |
更多>>
From December 31, 2013 to December 31, 2014
Issuance of shares and warrants, including at the market offering, net of $881 issuance costs
Vesting of restricted stock
Taxes withheld in respect of share issuance
|
2014-12-31 |
| 2014-11-12 | 4240.13 | 未披露 |
更多>>
On November 7, 2014, we sold 6,261,846 shares of our common stock and warrants to purchase 3,130,923 shares of our common stock in a registered direct offering.
|
2014-11-12 |
| 2014-10-27 | 3613.45 | 未披露 | 定期报告 | 2014-10-14 |
| 2014-11-12 | 3510.70 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-08-04 | 3518.15 | 未披露 | 定期报告 | 2014-08-04 |
| 2014-07-24 | 3415.90 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-07 | 3498.34 | 未披露 | 定期报告 | 2014-05-06 |
| 2014-05-07 | 3405.41 | 未披露 | 定期报告 | 2014-03-31 |
| 2014-09-25 | 3492.60 | 未披露 | 定期报告 | 2014-02-25 |
| 2014-02-26 | 3398.33 | 未披露 |
更多>>
from JUNE 30, 2013 to DECEMBER 31, 2013
Issuance of shares
Exercise of options by employees and non- employees
|
2013-12-31 |
| 2013-11-12 | 3451.26 | 未披露 | 定期报告 | 2013-11-11 |
| 2013-11-12 | 3396.60 | 未披露 | 定期报告 | 2013-09-30 |
| 2013-09-17 | 3451.26 | 未披露 | 定期报告 | 2013-09-16 |
| 2013-09-17 | 3388.88 | 未披露 |
更多>>
from JUNE 30, 2012 to JUNE 30, 2013
Issuance of shares - public offering, net of $2,121 issuance costs
Issuance of shares
Exercise of Warrants
Exercise of options by employees and non-employees
Shares of common stock used to satisfy tax withholding obligations
2013 Exchange agreement: Induced conversion of convertible debt
|
2013-06-30 |
| 2013-05-07 | 3431.69 | 未披露 | 定期报告 | 2013-05-07 |
| 2013-04-11 | 3109.82 | 未披露 |
更多>>
All share amounts are adjusted for the one-for-four reverse stock split that occurred on December 21, 2012.
|
2013-04-11 |
| 2013-05-07 | 1820.48 | 未披露 | 定期报告 | 2013-03-31 |
| 2013-03-22 | 1859.82 | 未披露 | 定期报告 | 2013-03-18 |
| 2013-03-05 | 1860.12 | 未披露 | 定期报告 | 2013-02-28 |
| 2013-02-04 | 1860.47 | 未披露 | 定期报告 | 2013-02-04 |
| 2013-02-04 | 1802.67 | 未披露 | 定期报告 | 2012-12-31 |
| 2012-11-09 | 1784.37 | 未披露 |
更多>>
a one-for-four reverse stock split of our common stock that is expected to occur the day immediately following the effectiveness of the registration statement
|
2012-11-06 |
| 2012-11-02 | 7137.50 | 未披露 | 定期报告 | 2012-11-01 |
| 2012-10-29 | 1775.03 | 未披露 |
更多>>
a one-for-four reverse stock split of our common stock that is expected to occur the day immediately following the effectiveness of the registration statement
|
2012-10-23 |
| 2012-11-02 | 6859.69 | 未披露 | 定期报告 | 2012-09-30 |
| 2012-09-24 | 6851.19 | 未披露 | 定期报告 | 2012-09-21 |
| 2012-09-24 | 6816.02 | 未披露 | 定期报告 | 2012-06-30 |
From July 30, 2025 to September 30, 2025
Exercise of pre-funded warrants
Exercise of Warrants Series I to 10,561,685 pre-funded warrants and 943,641 common stock, net of $891 issuance costs
Issuance of common stock, included at the market offering and 9,764,804 pre-funded warrants net of $3,126 issuance costs
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 34,712 shares
The Series I warrants were converted into 2,352,393 common shares
From April 1, 2025 to June 30, 2025
Exercise of pre-funded warrants
Exercise of Warrants Series I to common stock, net of $109 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 258,912 shares
From January 1, 2025 to March 31, 2025
Exercise of pre-funded warrants
Issuance of common stock, included at the market offering net of $22 issuance costs
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 29,295 shares
From January 1, 2024 to December 31, 2024
Balance, value
Exercise of pre-funded warrants
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs
Issuance of common stock, included at the market offering net of $81 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 128,660 shares
From July 1, 2024 to September 30, 2024
Exercise of pre-funded warrants
Issuance of common shares, Included at the market offering net of $1 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award
On July 1, 2024, InspireMD, Inc. Announced the completion of the full exercise of 12.9 million of the Company's Series H warrants. The Series H warrants were converted into 292,996 of common shares.
From April 1, 2024 to June 30, 2024
Exercise of pre-funded warrants
Exercise of Warrants Series H to 12,621,090 pre-funded warrants and 292,996 common stock, net of $1,000 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 37,292 shares
From January 1, 2024 to March 31, 2024
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 75,090 shares
From January 1, 2023 to December 31,2023
Exercise of pre-funded warrants
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 29,695 shares
From July 1, 2023 to September 30, 2023
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, net of forfeitures of 9,749 shares
From January 1, 2023 to March 31, 2023
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 4,270 shares
From December 31, 2021 to December 31, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 10,832 shares
From July 1, 2022 to September 30, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 1,581 shares
From April 1, 2022 to June 30, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award
From January 1, 2022 to March 31, 2022
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 4,563 share
From December 31, 2020 to December 31, 2021
Issuance of common shares, including at the market offering net of $2,024 issuance costs
Exercise of Warrants F
Exercise of Warrants G
Conversion of Series B Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 20,822 shares
Round up of shares due to reverse stock split effectuated on April 26, 2021
From July 1, 2021 to September 30, 2021
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 13,077 shares
Round up of shares due to reverse stock split effectuated on April 26, 2021
From April 1, 2021 to June 30, 2021
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 2,683 shares
Round up of shares due to reverse stock split effectuated on April 26, 2021
From January 1, 2021 to April 27, 2021
Issuance of common shares, including at the market offering net of $2,018 issuance costs
Exercise of Warrants F
Exercise of Warrants G
Conversion of Series B Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 3,276 shares
InspireMD, Inc. today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. The number of authorized shares of the Company’s common stock will remain at 150,000,000, while the number of outstanding shares will be reduced from approximately 118.0 million to 7.9 million. No fractional shares will be issued following the reverse stock split.
1.Units offered by the company: 29,032,258 units, each consisting of one share of common stock.
2.Based on 71,835,287 shares of common stock outstanding as of February 3, 2021.
From December 31, 2019 to December 31, 2020
Exercise of pre-funded warrants
Settlement of restricted stock units in shares of common stock
Issuance of common shares, including at the market offering net of $1,110 issuance costs
Exercise of Warrants F
Exercise of Unit Purchase Option
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 55,755 shares
From July 1, 2020 to September 30, 2020
Issuance of common shares at the market offering, net of $110 issuance costs
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 1,484 shares
From April 1, 2020 to June 30, 2020
Exercise of pre-funded warrants
Issuance of common shares, net of $835 issuance costs
Exercise of Warrants F
Exercise of Unit Purchase Option to common shares
Conversion of Series C Convertible Preferred Stock to common shares
1.Units offered by us 7,635,800 units, each consisting of one share of our common stock and/or one Series F Warrant to purchase one share of our common stock.
2.The number of shares of common stock to be outstanding immediately after this offering is based on 4,338,910 shares of our common stock outstanding as of June 2, 2020
From January 1, 2020 to March 31, 2020
Exercise of pre-funded warrants
Settlement of restricted stock units in shares of common stock
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 40,000 shares
from December 31, 2018 to December 31, 2019
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of $1,177 issuance costs
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of 838 shares
from June 30, 2019 to September 30, 2019
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of $710 issuance costs
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 142 shares
from March 31, 2019 to June 30,2019
Issuance of common shares, net of $467 issuance costs
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 483 shares
From December 31, 2018 to April 1, 2019
Exercise of pre-funded warrants
Conversion of Series C Convertible Preferred Stock to common shares
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 212 shares
InspireMD, Inc. announced that its Board of Directors has approved a one-for-fifty reverse stock split of its common stock that is scheduled to become effective after trading closes on March 29, 2019. The number of authorized shares of the Company’s common stock will remain at 150,000,000, while the number of outstanding shares will be reduced from approximately 44 million to 0.9 million. No fractional shares will be issued following the reverse stock split.
from December 31, 2017 to December 31, 2018
Issuance of common shares, warrants, Pre-funded warrants and exercise of pre-funded warrants, net of $2,206 issuance costs
Conversion of Series B Convertible Preferred Stock to common shares
Conversion of Series C Convertible Preferred Stock to common shares
Exercise of Unit Purchase Option
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 201 shares
Classification of Series C Convertible Preferred Stock
Redemption of Series D Preferred Stock
From December 31, 2017 to September 30, 2018
Issuance of common shares, warrants, Pre-funded warrants and exercise of pre-funded warrants, net of $2,171 issuance costs
Conversion of Series B Preferred Stock to common shares
Conversion of Series C Preferred Stock to common shares
Exercise of Unit Purchase Option
Share-based compensation related to restricted stock and stock options award, net of forfeitures of 121 shares
Redemption of Series C Preferred Stock
Redemption of Series D Preferred Stock
From December 31, 2017 to JUNE 22, 2018
Issuance of common shares, net of $1,053 issuance costs
Redemption of Series D Preferred Stock
Conversion of Series B Preferred Stock to common shares
Conversion of Series C Preferred Stock to common shares
Exercise of Unit Purchase Option
Redemption of Series C Preferred Stock
From December 31, 2017 to March 31, 2018
Issuance of common shares, net of $496 issuance costs
Redemption of Series D Preferred Stock
Conversion of Series B Preferred Stock to common shares
Conversion of Series C Preferred Stock to common shares
Exercise of Unit Purchase Option
from December 31, 2016 to February 8, 2018
Issuance of preferred shares and warrants, net of $776 issuance costs
Issuance of preferred shares, net of $90 issuance costs
Conversion of preferred B shares to common shares
Conversion of preferred C shares to common shares
Share-based compensation related to restricted stock award, net of forfeitures of 202 shares
Taxes withheld in respect of share issuance
InspireMD, Inc. today announced a 1-for-35 reverse split of its common stock, effective as of February 7, 2018. Beginning on February 8, 2018.The number of authorized shares of the Company's common stock will remain at 150,000,000, while the number of outstanding shares will be reduced from approximately 58.6 million to 1.7 million.
from December 31, 2015 to December 31, 2016
Issuance of common stock, preferred shares and warrants, net of $1,966 issuance costs
Conversion of preferred shares to common shares
Share-based compensation related to restricted stock award, net of forfeitures of 1,266 shares
Exercise of options by employee and non-employee
Issuance of shares for options cancelled
Taxes withheld in respect of share issuance
The company today announced a 1-for-25 reverse split of its common stock, effective as of October 7, 2016. Beginning on October 10, 2016, the Company's common stock will trade on the NYSE MKT on a split adjusted basis.
The company today announced a 1-for-25 reverse split of its common stock, effective as of October 7, 2016. Beginning on October 10, 2016, the Company's common stock will trade on the NYSE MKT on a split adjusted basis.
from December 31, 2014 to December 31, 2015
Issuance of shares and warrants, net of $1,315 issuance costs
Vesting of restricted stock
Taxes withheld in respect of share issuance
On October 1, 2015, the Company effectuated a one-for-ten reverse stock split of its common stock.
On September 30, 2015, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-ten reverse stock split of its common stock
From December 31, 2013 to December 31, 2014
Issuance of shares and warrants, including at the market offering, net of $881 issuance costs
Vesting of restricted stock
Taxes withheld in respect of share issuance
On November 7, 2014, we sold 6,261,846 shares of our common stock and warrants to purchase 3,130,923 shares of our common stock in a registered direct offering.
from JUNE 30, 2013 to DECEMBER 31, 2013
Issuance of shares
Exercise of options by employees and non- employees
from JUNE 30, 2012 to JUNE 30, 2013
Issuance of shares - public offering, net of $2,121 issuance costs
Issuance of shares
Exercise of Warrants
Exercise of options by employees and non-employees
Shares of common stock used to satisfy tax withholding obligations
2013 Exchange agreement: Induced conversion of convertible debt
All share amounts are adjusted for the one-for-four reverse stock split that occurred on December 21, 2012.
a one-for-four reverse stock split of our common stock that is expected to occur the day immediately following the effectiveness of the registration statement
a one-for-four reverse stock split of our common stock that is expected to occur the day immediately following the effectiveness of the registration statement